We are thrilled to announce (and this hit the press today) our groundbreaking partnership with KVK-Tech, a renowned Chemicals Manufacturing and Controls (CMC) company, to develop our unique asset SJP-100, a revolutionary anti-inflammatory injectable that has the potential to transform the lives of millions of patients worldwide.
Our team of dedicated scientists and researchers, along with the expertise and resources of our CMC partner, are confident in our ability to accelerate the development process and bring this innovative treatment to market faster than ever before. Jackie Iversen RPh MS, Co-Founder and Chief Clinical Officer, underscores the significance of this advance, stating, “This new offering will absolutely change the game in hospital settings for the silent killer otherwise known as runaway inflammation and as such, represents a momentous step forward in addressing an utterly massive unmet need.”
The development of a novel anti-inflammatory injectable would be a game-changer in critical care units, where patients often face life-threatening complications due to runaway inflammation. This partnership is a testament to our company’s vision and unwavering commitment to improving patient outcomes. We look forward to sharing more updates with you as we continue to make progress on this exciting project.